Meine Ordination ist Übersiedelt!
Die neue Adresse lautet:
Ordinationszentrum und Vorsorgezentrum der Confraternität
Skodagasse 32
1080 Wien
Ordinationszeiten:
Donnerstag Nachmittag nach Vereinbarung
Terminvereinbarungen und Kontaktaufnahme:
Montag bis Freitag von 08:00 bis 19:00 Uhr
unter der Telefonnnummer +43 1 40114 5701
oder per E-Mail unter
ordinationszentrum@confraternitaet.at
Nicht mehr anzeigen
Publikationen
Publikationsliste Rupert Bartsch
Publikationen in Journalen mit Peer Review
- Tendl-Schulz KA, Rössler F, Wimmer P, Heber UM, Mittlböck M,
Kozakowski N, Pinker K, Bartsch R, Dubsky P, Fitzal F, Filipits
M, Eckel FC, Langthaler EM, Steger G, Gnant M, Singer CF,
Helbich TH, Bago-Horvath Z. Factors influencing agreement of
breast cancer luminal molecular subtype by Ki67 labeling index
between core needle biopsy and surgical resection specimens.
Virchows Arch 2020;[Epub ahead of print].
- Fuereder T, Gunsilius E, Bartsch R, Hilbe W; editors of
memo. Circumnavigating the challenges of COVID-19 in oncology.
Memo 2020;7:1-4.
- Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stöger H,
Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Maria
Tea MK, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC,
Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C,
Bago-Horvath Z, Frantal S, Gnant M; Austrian Breast & Colorectal
Cancer Study Group. Efficacy and safety of the therapeutic
cancer vaccine tecemotide (L-BLP25) in early breast cancer:
Results from a prospective, randomised, neoadjuvant phase II
study (ABCSG 34). Eur J Cancer 2020;132:43-52.
- Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R,
Helfgott R, Marth C, Öhler L, Hubalek M, Lang A, Tinchon C,
Haslbauer F, Redl A, Hock K, Hennebelle M, Mraz B, Gnant M.
Efficacy and safety of everolimus plus exemestane in patients
with HR+, HER2- advanced breast cancer progressing on/after
prior endocrine therapy in routine clinical practice: Primary
results from the non-interventional study, STEPAUT. Breast
2020;50:64-70.
- Huober J, Bartsch R, Marmé F, Pagani O, Thomssen C. Luminal
Metastatic Breast Cancer. Breast Care (Basel) 2019;14:99-101.
- Obermeier HL, Riedl J, Ay C, Koder S, Quehenberger P,
Bartsch R, Kaider A, Zielinski CC, Pabinger I. The role of
ADAMTS-13 and von Willebrand factor in cancer patients: Results
from the Vienna Cancer and Thrombosis Study. Res Pract Thromb
Haemost 2019;3:503-514.
- Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M,
Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R,
Gnant M; ABCSG. Impact of Breast Surgery in Primary Metastasized
Breast Cancer: Outcomes of the Prospective Randomized Phase III
ABCSG-28 POSYTIVE Trial. Ann Surg 2019;269:1163-1169.
- Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R,
Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G,
Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ,
Di Leo A, Colleoni M, Viale G, Regan MM, André F; International
Breast Cancer Study Group and the Breast International Group.
Pembrolizumab plus trastuzumab in trastuzumab-resistant,
advanced, HER2-positive breast cancer (PANACEA): a single-arm,
multicentre, phase 1b-2 trial. Lancet Oncol 2019;20:371-382.
- Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F,
Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M,
Zielinski CC, Steger GG, Preusser M, Bartsch R. Continued
Endocrine Therapy Is Associated with Improved Survival in
Patients with Breast Cancer Brain Metastases. Clin Cancer Res
2019;25:2737-2744.
- Bartsch R, Bergen E. ASCO 2018: highlights in HER2-positive
metastatic breast cancer. Memo 2018;11:280-283.
- Füreder LM, Widhalm G, Gatterbauer B, Dieckmann K,
Hainfellner JA, Bartsch R, Zielinski CC, Preusser M, Berghoff
AS. Brain metastases as first manifestation of advanced cancer:
exploratory analysis of 459 patients at a tertiary care center.
Clin Exp Metastasis 2018;35:727-738.
- Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S,
Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF,
Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil
R. Ixazomib in combination with carboplatin in pretreated women
with advanced triple-negative breast cancer, a phase I/II trial
of the AGMT (AGMT MBC-10 trial). BMC Cancer 2018;18:1074.
- Tahmassebi A, Wengert GJ, Helbich TH, Bago-Horvath Z, Alaei
S, Bartsch R, Dubsky P, Baltzer P, Clauser P, Kapetas P, Morris
EA, Meyer-Baese A, Pinker K. Impact of Machine Learning With
Multiparametric Magnetic Resonance Imaging of the Breast for
Early Prediction of Response to Neoadjuvant Chemotherapy and
Survival Outcomes in Breast Cancer Patients. Invest Radiol
2019;54:110-117.
- Bartsch R, Bergen E. SABCS 2017: update on chemotherapy,
targeted therapy, and immunotherapy. Memo 2018;11:204-207.
- Bartsch R, Bergen E, Galid A. Current concepts and future
directions in neoadjuvant chemotherapy of breast cancer. Memo
2018;11:199-203.
- Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C,
Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC. CDK4/6
inhibitors in the treatment of patients with breast cancer:
summary of a multidisciplinary round-table discussion. ESMO Open
2018;3:e000368.
- Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M,
Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R,
Gnant M; ABCSG. Impact of Breast Surgery in Primary Metastasized
Breast Cancer: Outcomes of the Prospective Randomized Phase III
ABCSG-28 POSYTIVE Trial. Ann Surg 2018;[Epub ahaead of print].
- Kiesewetter B, Dediu M, Bartsch R. ESMO 2017-my personal
highlights. Memo 2018;11:77-79.
- Bergen ES, Bartsch R. My burning issues in the neoadjuvant
treatment for breast cancer. Memo 2018;11(1):27-30.
- Kowalczyk L, Bartsch R, Singer CF, Farr A. Adverse Events of
Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive
Breast Cancer Patients. Breast Care (Basel) 2017;12:401-408.
- Bartsch R. Ribociclib: a valuable addition to treatment
options in breast cancer? ESMO Open 2017;2:e000246.
- Bartsch R, Bergen E. ASCO 2017: highlights in breast cancer.
Memo. 2017;10:228-232.
- Balic M, Bartsch R, Bauernhofer T, Vrbanec D, Vrdoljak E.
Biosimilars in the Treatment of Breast Cancer. Breast Care
(Basel) 2017;12:192-194.
- Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter
F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R,
Schur S, Watzke HH, Zielinski CC, Preusser M. Decreased body
mass index is associated with impaired survival in lung cancer
patients with brain metastases: A retrospective analysis of 624
patients. Eur J Cancer Care (Engl) 2017;[Epub ahead of print].
- Dediu M, Gerger A, Zojer N, Bartsch R. My personal
highlights of ESMO 2016. MEMO 2017;10:46-47.
- Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A,
Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA,
Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits
M, Gnant M. Pathological Complete Response to Neoadjuvant
Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified
Early Breast Cancer. Clin Cancer Res 2017; 23:3676-3683.
- Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G,
Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC,
Weller M, Preusser M. Combining standard clinical blood values
for improving survival prediction in patients with newly
diagnosed brain metastases-development and validation of the
LabBM score. Neuro Oncol 2017; 19:1255-1262.
- Pluschnig U, Haslik W, Bartsch R, Mader RM. Extravasation
emergencies: state-of-the-art management and progress in
clinical research. MEMO 2016;9:226-230.
- Bartsch R, Bergen E. ASCO 2016: highlights in breast cancer.
MEMO 2016;9:211-214.
- Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U,
Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P,
Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M.
Survival prediction using temporal muscle thickness measurements
on cranial magnetic resonance images in patients with newly
diagnosed brain metastases. Eur Radiol 2017; 27:3167-3173.
- Bartsch R, de Azambuja E. I-SPY 2: optimising cancer drug
development in the 21st century. ESMO Open 2016;1:e000113.
- Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R,
Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger
M, Zielinski CC. The European Society for Medical Oncology
Magnitude of Clinical Benefit Scale in daily practice: a single
institution, real-life experience at the Medical University of
Vienna. ESMO Open 2016;1:e000066.
- Marhold M, Bartsch R, Zielinski C. Recent developments and
translational aspects in targeted therapy for metastatic breast
cancer. ESMO Open 2016;1:e000036.
- Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann
K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R,
Preusser M. Descriptive statistical analysis of a real life
cohort of 2419 patients with brain metastases of solid cancers.
ESMO Open 2016;1:e000024.
- Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G,
Dieckmann K, Birner P, Bartsch R, Preusser M. Tumor infiltrating
lymphocytes and PD-L1 expression in brain metastases of small
cell lung cancer (SCLC). J Neurooncol 2016;130:19-29.
- Minarikova L, Bogner W, Pinker K, Valkovič L, Zaric O,
Bago-Horvath Z, Bartsch R, Helbich TH, Trattnig S, Gruber S.
Investigating the prediction value of multiparametric magnetic
resonance imaging at 3 T in response to neoadjuvant chemotherapy
in breast cancer. Eur Radiol 2017;27:1901-1911.
- Spick C, Bickel H, Pinker K, Bernathova M, Kapetas P, Woitek
R, Clauser P, Polanec SH, Rudas M, Bartsch R, Helbich TH,
Baltzer PA. Diffusion-weighted MRI of breast lesions: a
prospective clinical investigation of the quantitative imaging
biomarker characteristics of reproducibility, repeatability, and
diagnostic accuracy. NMR Biomed 2016;29:1445-1453.
- Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A,
Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M,
Bachleitner-Hofmann T, Oehler R. Prognostic value of HMGB1 in
early breast cancer patients under neoadjuvant chemotherapy.
Cancer Med 2016;5:2350-2358.
- Gnant M, Steger GG, Bartsch R. Pathological complete
remission and long-term outcome-what do we know in 2016? Lancet
Oncol 2016;17:693-694.
- Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P,
Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger
GG, Preusser M, Bartsch R. Prognostic impact of breast cancer
subtypes in elderly patients. Breast Cancer Res Treat
2016;157:91-99.
- Minichsdorfer C, Füreder T, Mähr B, Berghoff AS, Heynar H,
Dressler A, Gnant M, Zielinski C, Bartsch R. A Cross-Sectional
Study of Patients' Satisfaction With Totally Implanted Access
Ports. Clin J Oncol Nurs 2016;20:175-180.
- Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G,
Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq
A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser
M. Density of tumor-infiltrating lymphocytes correlates with
extent of brain edema and overall survival time in patients with
brain metastases. Oncoimmunology 2015;5:e1057388.
- Thallinger C, Lang I, Kuhar CG, Bartsch R, Singer CF,
Petruzelka L, Melichar B, Knittelfelder R, Brodowicz T,
Zielinski C. Phase II study on the efficacy and safety of
Lapatinib administered beyond disease progression and combined
with vinorelbine in HER-2/neu- positive advanced breast cancer:
results of the CECOG LaVie trial.BMC Cancer 2016;16:121.
- Steger GG, Gnant M, Bartsch R. Palbociclib for the treatment
of postmenopausal breast cancer - an update. Expert Opin
Pharmacother 2016;17:255-263.
- Bartsch R, Gnant M,
Steger GG. Bevacizumab: no comeback in early breast cancer?
Lancet Oncol 2015;16:1001-1003.
- Bartsch R, Berghoff
AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K,
Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger
GG, Preusser M. Activity of T-DM1 in Her2-positive breast cancer
brain metastases. Clin Exp Metastasis 2015;32:729-737.
- Promberger R, Dubsky P, Mittlböck M, Ott J, Singer C,
Seemann R, Exner R, Panhofer P, Steger G, Bergen E, Gnant M,
Jakesz R, Bago-Horvath Z, Rudas M, Bartsch R. Postoperative CMF
Does Not Ameliorate Poor Outcomes in Women With Residual
Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel
Chemotherapy. Clin Breast Cancer 2015;15:505-511.
- Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H,
Lax S, Herz W, Dubsky P, Bartsch R, Kronenwetter R, Gnant M. The
genomic expression test EndoPredict is a prognostic tool for
identifying risk of local recurrence in postmenopausal endocrine
receptor-positive, her2neu-negative breast cancer patients
randomised within the prospective ABCSG 8 trial. Br J Cancer
2015;112:1405-1410.
- Zagouri F, Liakou P, Bartsch R,
Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC,
Dimopoulos MA, Azim HA Jr. Discrepancies between ESMO and NCCN
breast cancer guidelines: An appraisal. Breast 2015;24:513-523.
- Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C,
Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant
M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch
R. Taxanes plus trastuzumab compared to oral vinorelbine plus
trastuzumab in HER2-overexpressing metastatic breast cancer.
Breast Care (Basel) 2014;9:344-3448.
- Haslik W, Hacker
S, Felberbauer FX, Thallinger C, Bartsch R, Kornauth C,
Deutschmann C, Mader RM. Port-a-Cath® extravasation of vesicant
cytotoxics: Surgical options for a rare complication of cancer
chemotherapy. Eur J Surg Oncol 2015;41:378-385.
- Pluschnig U, Haslik W, Bayer G, Soleiman A, Bartsch R, Lamm W,
Steger GG, Zielinski CC, Mader RM. Outcome of chemotherapy
extravasation in a large patient series using a standardised
management protocol. Support Care Cancer 2015;23:1741-1748.
- Bergen ES, Berghoff AS, Rudas M, Preusser M, Bartsch R.
Breast cancer brain metastases responding to lapatinib plus
capecitabine as second-line primary systemic therapy. Anticancer
Drugs 2015; 26:579-581.
- Gnant M, Steger GG, Bartsch
R. CDK4/6 inhibitors in luminal breast cancer. Lancet Oncol
2015;16:2-3.
- Gnant M, Mlineritsch B, Stoeger H,
Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M,
Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W,
Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G,
Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R; on
behalf of the Austrian Breast and Colorectal Cancer Study Group
Vienna Austria. Zoledronic acid combined with adjuvant endocrine
therapy of tamoxifen versus anastrozol plus ovarian function
suppression in premenopausal early breast cancer: final analysis
of the Austrian Breast and Colorectal Cancer Study Group Trial
12. Ann Oncol 2015;26:313-320.
- Berghoff AS, Ricken G,
Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Höller C,
Preusser M. Tumour-infiltrating lymphocytes and expression of
programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Histopathology 2015;66:289-99.
- Berghoff AS, Bartsch
R, Wöhrer A, Streubel B, Birner P, Kros JM, Brastianos PK, von
Deimling A, Preusser M. Predictive molecular markers in
metastases to the central nervous system: recent advances and
future avenues. Acta Neuropathol 2014;128:879-891.
- Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M,
Widhalm G, Hainfellner JA, Dieckmann K, Pichler J, Hutterer M,
Melchardt T, Bartsch R, Zielinski CC, Birner P, Preusser M.
Differential role of angiogenesis and tumor cell proliferation
in brain metastases according to primary tumor type: analysis of
639 cases. Neuropathol Appl Neurobiol 2015;41:e41-55.
- Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA,
Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K,
Weller M, Goodman SL, Birner P, Preusser M. αvβ3, αvβ5 and αvβ6
integrins in brain metastases of lung cancer. Clin Exp
Metastasis 2014;31:841-851.
- Berghoff AS, Bartsch R,
Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M,
Streubel B, Dubsky P, Gnant M, Fitzal F, Zielinski CC, Birner P.
Co-overexpression of HER2/HER3 is a predictor of impaired
survival in breast cancer patients. Breast 2014;23:637-643.
- Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retèl
VP, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R,
Dubsky P. The multigene signature MammaPrint impacts on
multidisciplinary team decisions in ER+, HER2- early breast
cancer. Br J Cancer 2014;111:837-842.
- Pinker K,
Bogner W, Baltzer P, Karanikas G, Magometschnigg H, Brader P,
Gruber S, Bickel H, Dubsky P, Bago-Horvath Z, Bartsch R, Weber
M, Trattnig S, Helbich TH. Improved differentiation of benign
and malignant breast tumors with multiparametric
18fluorodeoxyglucose positron emission tomography magnetic
resonance imaging: a feasibility study. Clin Cancer Res
2014;20:3540-3539.
- Lück HJ, Untch M, Jackisch C,
Zielinski C, Bartsch R. Optimal Sequencing of Anti-HER2 Therapy.
Breast Care (Basel) 2014;9:138-140.
- Berghoff AS, Sax
C, Klein M, Furtner J, Dieckmann K, Gatterbauer B, Widhalm G,
Rudas M, Zielinski CC, Bartsch R, Preusser M. Alleviation of
brain edema and restoration of functional independence by
bevacizumab in brain-metastatic breast cancer: a case report.
Breast Care (Basel) 2014;9:134-136.
- Gnant M, Bartsch
R, Steger GG. HER2-positive breast cancer: a new piece of the
puzzle. Lancet Oncol 2014;15:668-669.
- Pinker K,
Bogner W, Baltzer P, Gruber S, Bickel H, Brueck B, Trattnig S,
Weber M, Dubsky P, Bago-Horvath Z, Bartsch R, Helbich TH.
Improved diagnostic accuracy with multiparametric magnetic
resonance imaging of the breast using dynamic contrast-enhanced
magnetic resonance imaging, diffusion-weighted imaging, and
3-dimensional proton magnetic resonance spectroscopic imaging.
Invest Radiol 2014;49:421-430.
- Birner P, Bartsch R,
Schreiber M, Dubsky P, Kenner L. New approaches for breast
cancer: should Ret kinase be considered as a novel therapeutic
target? Future Oncol 2014;10:333-336.
- Foedermayr M,
Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M,
Dubsky P, Fitzal F, Gnant M, Steger GG, Weltermann A, Zielinski
CC, Zach O, Bartsch R. BRCA-1 methylation and TP53 mutation in
triple-negative breast cancer patients without pathological
complete response to taxane-based neoadjuvant chemotherapy.
Cancer Chemother Pharmacol 2014;73:771-778.
- Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S,
Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil
R. Hypertension as a predictive marker for bevacizumab in
metastatic breast cancer: results from a retrospective
matched-pair analysis. Anticancer Res 2014;34:227-233.
- Haslik W, Pluschnig U, Steger GG, Zielinski CC,
Schrögendorfer KF, Nedomansky J, Bartsch R, Mader RM.
Indocyanine green video angiography predicts outcome of
extravasation injuries. PLoS One 2014;9:e103649.
- Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P,
Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart
A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M,
Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development
Association (BDA). Present and future breast cancer
management--bench to bedside and back: a positioning paper of
academia, regulatory authorities and pharmaceutical industry.
Ann Oncol 2014;25:773-780.
- Steger GG, Greil R, Lang
A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R,
Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer
AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC,
Fesl C, Gnant M; Austrian Breast and Colorectal Study Group
(ABCSG). Epirubicin and docetaxel with or without capecitabine
as neoadjuvant treatment for early breast cancer: final results
of a randomized phase III study (ABCSG-24). Ann Oncol
2014;25:366-371.
- Gnant M, Filipits M, Greil R,
Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W,
Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R,
Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S,
Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and
Colorectal Cancer Study Group. Predicting distant recurrence in
receptor-positive breast cancer patients with limited
clinicopathological risk: using the PAM50 Risk of Recurrence
score in 1478 postmenopausal patients of the ABCSG-8 trial
treated with adjuvant endocrine therapy alone. Ann Oncol
2014;25:339-345.
- Petricevic B, Laengle J, Singer J,
Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E,
Bergmann M. Trastuzumab mediates antibody-dependent
cell-mediated cytotoxicity and phagocytosis to the same extent
in both adjuvant and metastatic HER2/neu breast cancer patients.
J Transl Med 2013;11:307.
- Moshammer MI, Kalipciyan M,
Bartsch R, Steger GG, Sedivy R, Mader RM. Exosomal microRNA
transfer varies with specific microRNAs functional in colorectal
cancer and cellular differentiation. Int J Clin Pharmacol Ther
2014;52:87-88.
- Berghoff AS, Rajky O, Winkler F,
Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M,
Schittenhelm J, Preusser M. Invasion patterns in brain
metastases of solid cancers. Neuro Oncol 2013;15:1664-1672.
- Bartsch R, Berghoff AS, Preusser M. Breast cancer brain
metastases responding to primary systemic therapy with T-DM1. J
Neurooncol 2014;116:205-206.
- Steger GG, Bartsch R.
ASCO 2013: News in early stage and advanced breast cancer.
Magazine of European Medical Oncology 2013; 6:227-232.
- Zagouri F, Psaltopoulou T, Dimitrakakis C, Bartsch R,
Dimopoulos MA. Challenges in managing breast cancer during
pregnancy. J Thorac Dis 2013;5(Suppl.1):S62-67.
- Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Filipits M,
Bartsch R, Dimopoulos MA, Psaltopoulou T. Pertuzumab in breast
cancer: a systematic review. Clin Breast Cancer 2013;13:315-324.
- Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG,
Papadimitriou CA, Dimopoulos MA, Filipits M, Bartsch R.
Molecularly targeted therapies in metastatic pancreatic cancer:
a systematic review. Pancreas 2013;42:760-773.
- Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG,
Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos MA,
Bartsch R. Aromatase inhibitors with or without
gonadotropin-releasing hormone analogue in metastatic male
breast cancer: a case series. Br J Cancer 2013;108:2259-2263.
- Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS,
Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M.
Intrathecal administration of trastuzumab for the treatment of
meningeal carcinomatosis in HER2-positive metastatic breast
cancer: a systematic review and pooled analysis. Breast Cancer
Res Treat 2013;139:13-22.
- Zagouri F, Bago-Horvath Z,
Rössler F, Brandstetter A, Bartsch R, Papadimitriou CA,
Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A, Dimopoulos
MA, Filipits M. High MET expression is an adverse prognostic
factor in patients with triple-negative breast cancer. Br J
Cancer 2013;108:1100-1105.
- Arnold T, Michlmayr A,
Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant
M, Bergmann M, Bachleitner-Hofmann T, Oehler R. Plasma HMGB-1
after the initial dose of epirubicin/docetaxel in cancer. Eur J
Clin Invest 2013;43:286-291.
- Berghoff AS,
Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C,
Gnant M, Steger GG, Zielinski CC, Bartsch R. Impact of
HER-2-targeted therapy on overall survival in patients with
HER-2 positive metastatic breast cancer. Breast J
2013;19:149-155.
- Zagouri F, Sergentanis TN, Chrysikos
D, Bartsch R. Platinum derivatives during pregnancy in cervical
cancer: a systematic review and meta-analysis. Obstet Gynecol
2013;121(2 Pt 1):337-343.
- Körber MI, Klingenbrunner
S, Bartsch R, Steger GG, Mader RM. NF-κB addiction and
resistance to 5-fluorouracil in a multi-stage colon carcinoma
model. Int J Clin Pharmacol Ther 2013;51:35-37.
- Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M,
Steger G, Zografos G, Bartsch R. Fulvestrant and male breast
cancer: a case series. Ann Oncol 2013;24:265-266.
- Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA,
Dimopoulos MA, Bartsch R. Trastuzumab administration during
pregnancy: a systematic review and meta-analysis. Breast Cancer
Res Treat 2013;137:349-357.
- Bartsch R, Berghoff AS,
Preusser M. Optimal management of brain metastases from breast
cancer. Issues and considerations. CNS Drugs 2013;27:121-134.
- Bartsch R, Preusser M. Primary systemic treatment of
breast-cancer brain metastases. Lancet Oncol 2013;14:8-9.
- Berghoff AS, Bago-Horvath Z, Ilhan-Mutlu A, Magerle M,
Dieckmann K, Marosi C, Birner P, Widhalm G, Steger GG, Zielinski
CC, Bartsch R, Preusser M. Brain-only metastatic breast cancer
is a distinct clinical entity characterised by favourable median
overall survival time and a high rate of long-term survivors. Br
J Cancer 2012;107:1454-1458.
- Zagouri F, Sergentanis
TN, Chrysikos D, Filipits M, Bartsch R. mTOR inhibitors in
breast cancer: a systematic review. Gynecol Oncol
2012;127:662-672.
- Zagouri F, Sergentanis TN,
Chrysikos D, Filipits M, Bartsch R. Taxanes for ovarian cancer
during pregnancy: a systematic review. Oncology 2012;83:234-238.
- Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG,
Greil R, Zielinski CC, Bartsch R. Influence of the American ODAC
statement on Austrian bevacizumab prescribing practice for
metastatic breast cancer. Oncologist 2012;17:e13-17.
- Dubsky P, Bartsch R. Bisphosphonates in early breast cancer.
Lancet Oncol 2012;13:660-661.
- Zagouri F, Sergentanis
TN, Chrysikos D, Filipits M, Bartsch R. Molecularly targeted
therapies in cervical cancer. A systematic review. Gynecol Oncol
2012;126:291-303.
- Hubalek M, Bartsch R, Gnant M, Kapp
KS, Lang A, Lax S, Lukas P, Neunteufel W, Pristauz G, Reitsamer
R, Sandbichler P, Schrenk P, Singer C, Tamussino K, Tschmelitsch
J, Zeimet AG, Marth C. Axillary Dissection in the Case of
Positive Sentinel Lymph Nodes: Results of the Innsbruck
Consensus Conference. Geburtshilfe Frauenheilkd 2012;72:293-298.
- Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C,
Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal
F, Gnant M, Zielinski CC, Steger GG. Ovarian function
suppression and fulvestrant as endocrine therapy in
premenopausal women with metastatic breast cancer. Eur J Cancer
2012;48:1932-1938.
- Steger GG, Bartsch R. Trends and
Novel Approaches in Neoadjuvant Treatment of Breast Cancer.
Breast Care (Basel) 2011;6:427-433.
- Dubsky PC,
Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W,
Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M,
Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R,
Steger GG, Greil R, Filipcic L, Gnant M. Tamoxifen and
anastrozole as a sequencing strategy: a randomized controlled
trial in postmenopausal patients with endocrine-responsive early
breast cancer from the Austrian Breast and Colorectal Cancer
Study Group. J Clin Oncol 2012;30:722-728.
- Berghoff
A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M,
Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader
RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.
Brain metastases free survival differs between breast cancer
subtypes. Br J Cancer 2012;106:440-446.
- Preusser M,
Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R,
Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling
A. Brain metastases: pathobiology and emerging targeted
therapies. Acta Neuropathol 2012;123:205-222.
- Bartsch R, Dubsky PC, Loibl S, Steger G. Opinions on the ASCO
2011 Annual Meeting. Breast Care (Basel) 2011;6:315-319.
- Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky
P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K,
Mader RM, Gnant M, Zielinski CC, Steger GG. Impact of anti-HER2
therapy on overall survival in HER2-overexpressing breast cancer
patients with brain metastases. Br J Cancer 2012;106:25-31.
- Steger GG, Bartsch R. Denosumab for the treatment of
bone metastases in breast cancer: evidence and opinion. Ther Adv
Med Oncol 2011;3:233-243.
- Fiegl M, Mlineritsch B,
Hubalek M, Bartsch R, Pluschnig U, Steger GG. Single-agent
pegylated liposomal doxorubicin (PLD) in the treatment of
metastatic breast cancer: results of an Austrian observational
trial. BMC Cancer 2011;11:373.
- Fitzal F, Mittlboeck
M, Steger G, Bartsch R, Rudas M, Dubsky P, Riedl O, Jakesz R,
Gnant M. Neoadjuvant chemotherapy increases the rate of breast
conservation in lobular-type breast cancer patients. Ann Surg
Oncol 2012;19:519-526.
- Gampenrieder SP, Bartsch R,
Matzneller P, Pluschnig U, Dubsky P, Gnant MX, Zielinski CC,
Steger GG. Capecitabine and Vinorelbine as an All-Oral
Chemotherapy in HER2-Negative Locally Advanced and Metastatic
Breast Cancer. Breast Care (Basel) 2010;5:158-162.
- Michlmayr A, Bachleitner-Hofmann T, Baumann S,
Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C,
Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G,
Gnant M, Bergmann M, Oehler R. Modulation of plasma complement
by the initial dose of epirubicin/docetaxel therapy in breast
cancer and its predictive value. Br J Cancer 2010;103:1201-1208.
- Fitzal F, Riedl O, Mittlböck M, Dubsky P, Bartsch R,
Steger G, Jakesz R, Gnant M. Oncologic safety of breast
conserving surgery after tumour downsizing by neoadjuvant
therapy: a retrospective single centre cohort study. Breast
Cancer Res Treat 2011;127:121-128.
- Bartsch R,
Ziebermayr R, Zielinski CC, Steger GG. Triple-negative breast
cancer. Wien Med Wochenschr 2010;160:174-181.
- Bartsch R, Ziebermayr R. ASCO 2010: update on metastatic breast
cancer. MEMO 2010;3:159-62.
- Kierner KA, Gartner V,
Bartsch R, Hladschik-Kermer B, Gruber A, Hassler M, Watzke HH.
Attitudes towards palliative care in primary metastatic cancer:
a survey among oncologists. Wien Klin Wochenschr 2010;122:45-49.
- Wiedermann U, Wiltschke C, Jasinska J, Kundi M,
Zurbriggen R, Garner-Spitzer E, Bartsch R, Steger G, Pehamberger
H, Scheiner O, Zielinski CC. A virosomal formulated Her-2/neu
multi-peptide vaccine induces Her-2/neu-specific immune
responses in patients with metastatic breast cancer: a phase I
study. Breast Cancer Res Treat 2010;119:673-683.
- Fromm-Haidenberger S, Pohl G, Widder J, Kren G, Fitzal F,
Bartsch R, de Vries J, Zielinski C, Pötter R. Vienna
international summer school on experimental and clinical
oncology for medical students: an Austrian cancer education
project. J Cancer Educ 2010;25:51-54.
- Bartsch R,
Steger GG, Gnant M, Ziebermayr R. Breast Cancer: Rank Ligand
Inhibition. Breast Care (Basel) 2010;5:320-325.
- Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z,
Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C,
Gnant M, Zielinski CC, Steger GG. Predicting for activity of
second-line trastuzumab-based therapy in her2-positive advanced
breast cancer. BMC Cancer 2009;9:367.
- Tomova A,
Bartsch R, Brodowicz T, Tzekova V, Timcheva C, Wiltschke C,
Gerges DA, Pawlega J, Spanik S, Inbar M, Zielinski CC.
Concomitant docetaxel plus gemcitabine versus sequential
docetaxel followed by gemcitabine in anthracycline-pretreated
metastatic or locally recurrent inoperable breast cancer
patients: a prospective multicentre trial of the Central
European Cooperative Oncology Group (CECOG). Breast Cancer Res
Treat 2010;119:169-176.
- Bartsch R, Steger GG. Role
of denosumab in breast cancer. Expert Opin Biol Ther
2009;9:1225-1233.
- Bartsch R, Steger GG. The Role of
Supportive Therapy in the Era of Modern Adjuvant Treatment -
Current and Future Tools. Breast Care (Basel). 2009;4:167-176.
- Bartsch R, Mlineritsch B, Gnant M, Niernberger T,
Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M,
Pober M, Zielinski CC, Steger GG; Austrian Fulvestrant Registry.
The Austrian fulvestrant registry: results from a prospective
observation of fulvestrant in postmenopausal patients with
metastatic breast cancer. Breast Cancer Res Treat
2009;115:373-380.
- Fromm S, Bartsch R, Rudas M, de
Vries A, Wenzel C, Steger GG, Zielinski CC, Poetter R, Dieckmann
K. Factors influencing the time to development of brain
metastases in breast cancer. Breast 2008;17:512-516.
- Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H,
Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger
H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W,
Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal
Cancer Study Group. Anemia is a significant prognostic factor in
local relapse-free survival of premenopausal primary breast
cancer patients receiving adjuvant
cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin
Cancer Res 2008;14:2082-2087.
- Bartsch R, Wenzel C,
Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, Mader RM,
Dubsky P, Rottenfusser A, Gnant M, Zielinski CC, Steger GG.
Trastuzumab and gemcitabine as salvage therapy in heavily
pre-treated patients with metastatic breast cancer. Cancer
Chemother Pharmacol 2008;62:903-910.
- Bartsch R,
Steger GG. Adjuvant chemotherapy in breast cancer. MEMO
2008;1:91-98.
- Bartsch R, Wenzel C, Altorjai G,
Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger
GG. Capecitabine and trastuzumab in heavily pretreated
metastatic breast cancer. J Clin Oncol 2007;25:3853-3858.
- Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Mader RM,
Gnant M, Jakesz R, Rudas M, Zielinski CC, Steger GG. Her2 and
progesterone receptor status are not predictive of response to
fulvestrant treatment. Clin Cancer Res 2007;13(15 Pt
1):4435-4439.
- Bartsch R, Steger GG, Forstner B,
Wenzel C, Pluschnig U, Rizovski B, Altorjai G, Zielinski CC,
Mader RM. Expression of thymidine phosphorylase in peripheral
blood cells of breast cancer patients is not increased by
paclitaxel. BMC Clin Pharmacol 2007;7:7.
- Bartsch R,
Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G,
Rudas M, Mader RM, Poetter R, Zielinski CC, Steger GG.
Trastuzumab prolongs overall survival in patients with brain
metastases from Her2 positive breast cancer. J Neurooncol
2007;85:311-317.
- Bartsch R, Wenzel C, Zielinski CC,
Steger GG. HER-2-positive breast cancer: hope beyond
trastuzumab. BioDrugs 2007;21:69-77.
- Bartsch R,
Wenzel C, Steger GG. Trastuzumab in the management of early and
advanced stage breast cancer. Biologics 2007;1:19-31.
- Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G,
Zielinski CC, Lang A, Haid A, Jakesz R, Gnant M, Steger GG.
Invasive ductal carcinoma and invasive lobular carcinoma of
breast differ in response following neoadjuvant therapy with
epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat
2007;104:109-114.
- Bartsch R, Wenzel C, Altorjai G,
Pluschnig U, Bachleitner-Hoffmann T, Locker GJ, Rudas M, Mader
R, Zielinski CC, Steger GG. Results from an observational trial
with oral vinorelbine and trastuzumab in advanced breast cancer.
Breast Cancer Res Treat 2007;102:375-381.
- Bartsch R.
Comment on the letter to the editor „Hormone receptor status as
an independent variable affecting the survival of advanced
breast cancer patients with brain metastases“ (Hakan
Harputluoglu et al.). Radiother Oncol 2007;2:375.
- Bartsch R, Fromm S, Rudas M, Wenzel C, Harbauer S, Roessler K,
Kitz K, Steger GG, Weitmann HD, Poetter R, Zielinski CC,
Dieckmann K. Intensified local treatment and systemic therapy
significantly increase survival in patients with brain
metastases from advanced breast cancer - a retrospective
analysis. Radiother Oncol 2006;80:313-317.
- Bartsch
R, Woehrer S, Raderer M, Hejna M. Serum interleukin-6 levels in
patients with gastric MALT lymphoma compared to gastric and
pancreatic cancer. Anticancer Res 2006;26:3187-3190.
- Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Altorjai
G, Locker GJ, Mader R, Zielinski CC, Steger GG. Prognostic value
of monitoring tumour markers CA 15-3 and CEA during fulvestrant
treatment. BMC Cancer 2006;6:81.
- Bartsch R, Wenzel
C, Hussian D, Pluschnig U, Sevelda U, Koestler W, Altorjai G,
Locker GJ, Mader R, Zielinski CC, Steger GG. Analysis of
trastuzumab and chemotherapy in advanced breast cancer after the
failure of at least one earlier combination: an observational
study. BMC Cancer 2006;6:63.
- Bartsch R, Weitmann HD,
Pennwieser W, Wenzel C, Muschitz S, Baldass M, Hassler M, Marosi
C, Rössler K, Pötter R, Dieckmann K. Retrospective analysis of
re-irradiation in malignant glioma: a single-center experience.
Wien Klin Wochenschr 2005;117:821-826.
- Raderer M,
Wöhrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A,
Turetschek K, Jaeger U, Streubel B, Zielinski CC. Phase II study
of oxaliplatin for treatment of patients with mucosa-associated
lymphoid tissue lymphoma. J Clin Oncol 2005;23:8442-8446.
- Wöhrer S, Bartsch R, Hejna M, Drach J, Raderer M.
Routine application of the proton-pump inhibitor pantoprazole in
patients with gastric lymphoma undergoing chemotherapy. Scand J
Gastroenterol 2005;40:1222-1225.
- Steger GG, Bartsch
R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, Gnant
MF, Jakesz R, Zielinski CC. Fulvestrant ('Faslodex') in
pre-treated patients with advanced breast cancer: a
single-centre experience. Eur J Cancer 2005;41:2655-2661.
- Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U,
Locker GJ, Mader R, Zielinski CC, Steger GG. Oral vinorelbine
alone or in combination with trastuzumab in advanced breast
cancer: results from a pilot trial. Cancer Chemother Pharmacol
2006;57:554-558.
- Wenzel C, Locker GJ, Bartsch R,
Pluschnig U, Hussian D, Zielinski CC, Rudas M, Gnant MF, Jakesz
R, Steger GG. Preoperative second-line chemotherapy induces
objective responses in primary breast cancer. Wien Klin
Wochenschr 2005;117:48-52.
- Bartsch R, Wenzel C,
Sevelda U, Hussian D, Pluschnig U, Locker GJ, Mader R, Zielinski
CC, Steger GG. Darbepoetin alpha as treatment for anemia in
patients receiving chemotherapy: a single-center experience.
Anticancer Drugs 2005l;16:617-620.
- Wenzel C, Bartsch
R, Locker GJ, Hussian D, Pluschnig U, Sevelda U, Gnant MF,
Jakesz R, Zielinski CC, Steger GG. Preoperative chemotherapy
with epidoxorubicin, docetaxel and capecitabine plus
pegfilgrastim in patients with primary breast cancer. Anticancer
Drugs 2005;16:441-445.
- Wöhrer S, Streubel B, Bartsch
R, Chott A, Raderer M. Monoclonal immunoglobulin production is a
frequent event in patients with mucosa-associated lymphoid
tissue lymphoma. Clin Cancer Res 2004;10:7179-7181.
- Wenzel C, Hussian D, Bartsch R, Pluschnig U, Locker GJ, Rudas M,
Gnant MF, Jakesz R, Zielinkski CC, Steger GG. Preoperative
therapy with epidoxorubicin and docetaxel plus trastuzumab in
patients with primary breast cancer: a pilot study. J Cancer Res
Clin Oncol 2004;130:400-404.
- Wenzel C, Bartsch R,
Hussian D, Pluschnig U, Locker GJ, Sevelda U, Zielinski CC,
Steger GG. Zoledronate in a patient with pamidronate refractory
hypercalcemia syndrome. Support Care Cancer 2004;12:678-681.
- Wenzel C, Locker GJ, Bartsch R, Pluschnig U, Mader R,
Hussian D, Kramer G, Marberger M, Lintner C, Rauchenwald M,
Zielinski CC, Steger GG. Capecitabine monotherapy and in
combination with immunotherapy in the treatment of metastatic
renal cell carcinoma. Anticancer Drugs 2003;14:779-784.
- Steger GG, Wenzel C, Bartsch R, Rudas M, Gnant M, Zielinski
CC, Jakesz R. Preliminary results of a pilot-trial with
trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant
treatment of primary, operable breast cancer. Breast
2003;12(Suppl.1):S29-40.
Buchbeiträge
- Bartsch R, Steger GG. Denosumab – das Molekül: Erster klinischer Einsatz (German). In: Gnant M, Hadji P (Eds.).
Osteo-Onkologie – RANKL-Inhibition beim Mammakarzinom, pp 50-55. Uni-Med Verlag 2009.
- Bartsch R, Steger G. Mammakarzinom (German). In: Marian B (Ed.). Krankheit, Krankheitsursachen und -bilder, 5th Edition, pp
360-384. Facultas. wuv 2010.
- Bartsch R, Steger GG. Trastuzumab as adjuvant treatment for early stage Her2-positive breast cancer. In: Sibilia M, Zielinski
CC, Bartsch R, Grunt T (Eds.). Milestones in Drug Therapy: Drugs for HER-2-positive Breast Cancer, pp 33-50. Springer Basel 2011.
- De Vries C, Bartsch R. Die neoadjuvante Therapie des Mammakarzinoms (German). In: Kandioler D (Ed.). Manual der
chirurgische Krebstherapie, pp 98-101. Krause und Pachernegg 2011.
- Bartsch R, Steger GG. Guidelines zur palliative systemischen Therapie (German). In: Kandioler D (Ed.). Manual der chirurgische
Krebstherapie, pp 127-139. Krause und Pachernegg 2011.
Diese Website nutzt Cookies, um bestmögliche Funktionalität bieten zu können.